Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0213
REVIEW
|
Solid cancer: Evaluating potential efficacy of epigenetic drugs. |
|
Affiliation: Chee-Seng Ku, Cancer Science Institute of Singapore, National University of Singapore, Singapore.
E-mail: csikcs@nus.edu.sg |
Abstract
Current generation of targeted cancer drugs in the treatment of solid cancers, with the exceptions of trastuzumab and vemurafenib , resistance and disease progression limit the effectiveness of most signal transduction inhibitors available. Epigenomic drugs and microRNAs-based agents represent one of promising categories in clinical development to increase tumor cells sensitivity to combined therapeutics. Here, I discuss latest data and perspectives in overcoming current therapy resistance by treating solid tumors.
(Citation: Gastric & Breast Cancer 2012; 11(2): 102-107)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 23 April 2012 |
|
